JP2017511140A5 - - Google Patents

Download PDF

Info

Publication number
JP2017511140A5
JP2017511140A5 JP2016560673A JP2016560673A JP2017511140A5 JP 2017511140 A5 JP2017511140 A5 JP 2017511140A5 JP 2016560673 A JP2016560673 A JP 2016560673A JP 2016560673 A JP2016560673 A JP 2016560673A JP 2017511140 A5 JP2017511140 A5 JP 2017511140A5
Authority
JP
Japan
Prior art keywords
seq
variable region
antibody
chain variable
amino acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2016560673A
Other languages
English (en)
Japanese (ja)
Other versions
JP2017511140A (ja
JP6588922B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2015/023715 external-priority patent/WO2015153685A1/en
Publication of JP2017511140A publication Critical patent/JP2017511140A/ja
Publication of JP2017511140A5 publication Critical patent/JP2017511140A5/ja
Application granted granted Critical
Publication of JP6588922B2 publication Critical patent/JP6588922B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2016560673A 2014-03-31 2015-03-31 ヒト化百日咳抗体及びその使用 Expired - Fee Related JP6588922B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201461973141P 2014-03-31 2014-03-31
US61/973,141 2014-03-31
US201462046403P 2014-09-05 2014-09-05
US62/046,403 2014-09-05
PCT/US2015/023715 WO2015153685A1 (en) 2014-03-31 2015-03-31 Humanized pertussis antibodies and uses thereof

Publications (3)

Publication Number Publication Date
JP2017511140A JP2017511140A (ja) 2017-04-20
JP2017511140A5 true JP2017511140A5 (enExample) 2018-04-26
JP6588922B2 JP6588922B2 (ja) 2019-10-09

Family

ID=54241237

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2016560673A Expired - Fee Related JP6588922B2 (ja) 2014-03-31 2015-03-31 ヒト化百日咳抗体及びその使用

Country Status (8)

Country Link
US (3) US9512204B2 (enExample)
EP (1) EP3126385B1 (enExample)
JP (1) JP6588922B2 (enExample)
CN (1) CN106459183B (enExample)
AU (1) AU2015240834B2 (enExample)
CA (1) CA2941152C (enExample)
ES (1) ES2755957T3 (enExample)
WO (1) WO2015153685A1 (enExample)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2752396A1 (en) * 2010-09-17 2012-03-17 Board Of Regents, The University Of Texas System Pertussis antibodies and uses thereof
EP3126385B1 (en) * 2014-03-31 2019-09-18 Board Of Regents, The University Of Texas System Humanized pertussis antibodies and uses thereof
MD20160130A2 (ro) * 2014-04-27 2017-04-30 Ccam Biotherapeutics Ltd. Anticorpi umanizaţi contra CEACAM1
US11427647B2 (en) 2014-04-27 2022-08-30 Famewave Ltd. Polynucleotides encoding humanized antibodies against CEACAM1
CN107663240B (zh) * 2016-07-29 2021-01-12 中国人民解放军第四军医大学 高度糖基化cea特异性结合的单链抗体及其在检测和治疗上的应用
US20210332112A1 (en) * 2016-08-15 2021-10-28 Board Of Regents, The University Of Texas System Stabilized pertussis antibodies with extended half-life
US10538579B2 (en) 2016-08-15 2020-01-21 Board Of Regents, The University Of Texas System Bispecific pertussis antibodies
AU2018351072B9 (en) 2017-10-20 2024-09-05 Fred Hutchinson Cancer Center Systems and methods to produce B cells genetically modified to express selected antibodies
EP3995510A4 (en) * 2019-07-01 2023-11-08 Suzhou Alphamab Co., Ltd PERTUSSIS TOXIN BINDING PROTEIN
WO2024237730A1 (ko) * 2023-05-18 2024-11-21 한국과학기술연구원 항-엔도글린 항체 및 이의 용도

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1223529B (it) 1987-12-18 1990-09-19 Sclavo Spa Epitopo immunodominante protettivo contenuto nella subunita' s1 della tossina della pertosse
US6884879B1 (en) 1997-04-07 2005-04-26 Genentech, Inc. Anti-VEGF antibodies
US7754209B2 (en) 2003-07-26 2010-07-13 Trubion Pharmaceuticals Binding constructs and methods for use thereof
US7417133B2 (en) * 2004-02-27 2008-08-26 Institut Pasteur Methods for obtaining thermostable enzymes, DNA polymerase I variants from Thermus aquaticus having new catalytic activities, methods for obtaining the same, and applications of the same
WO2009042165A2 (en) * 2007-09-25 2009-04-02 Thomas Jefferson University Mutant botulinum neurotoxin serotype a polypeptide and uses thereof
CA2752396A1 (en) 2010-09-17 2012-03-17 Board Of Regents, The University Of Texas System Pertussis antibodies and uses thereof
WO2014160098A2 (en) * 2013-03-13 2014-10-02 Excelimmune, Inc. Bordetella specific human recombinant antibodies and uses thereof
EP3126385B1 (en) * 2014-03-31 2019-09-18 Board Of Regents, The University Of Texas System Humanized pertussis antibodies and uses thereof

Similar Documents

Publication Publication Date Title
JP2017511140A5 (enExample)
JP2012525128A5 (enExample)
AR109298A1 (es) Anticuerpos multiepitópicos y multivalentes que tienen actividad agonista y métodos de uso
JP2016507470A5 (enExample)
FI3484915T3 (fi) Uusia zikavirusepitooppeihin spesifisesti sitoutuvia vasta-aineita ja niiden käyttöjä
JP2020503001A5 (enExample)
JP2017500018A5 (enExample)
RU2018147413A (ru) PD-L1 специфические антитела
JP2014514346A5 (enExample)
JP2018508509A5 (enExample)
JP2016502515A5 (enExample)
JP2016506416A5 (enExample)
JP2014522843A5 (enExample)
JP2016503413A5 (enExample)
JP2010202664A5 (enExample)
JP2015501814A5 (enExample)
JP2013534532A5 (enExample)
JP2018505882A5 (enExample)
JP2015503909A5 (enExample)
JP2016525502A5 (enExample)
JP2014502955A5 (enExample)
JP2013534515A5 (ja) 受容体型チロシンキナーゼｃ−Ｍｅｔに対する抗体
JP2017507657A5 (enExample)
JP2017506669A5 (ja) 膠芽腫の治療に使用するための組成物及びその使用
JP2018518940A5 (enExample)